

Different Approaches

Organ system vs Organisms

- IE: what bacteria live where in the body?
- Skin vs GU Tract vs Oral Cavity all prone to different bugs.

Resources

- IDSA Guidelines
 - o https://www.idsociety.org/PracticeGuidelines/
- UK Antibiogram

Staphylococcus Staphylococcus Staphylococcus Staphylococcus

• ID Pharmacist

| 🐨 CareWeb - Clinician Deskt 🗙 🕂 | | | - 🗆 X |
|-----------------------------------|---|---|--|
| • www.hosp.uky.edu/careweb/r | carehome.asp?PageName=General&Section= | C Q Search | ☆ 白 ♣ ★ ♥ Ξ |
| HealthCar | re UK Resources - | | CareWeb |
| STAR Program | limited to break/fix, emergency, and standard ch | | ED Downtime Tool - |
| | to changes should be lifted following application information about changes and new functionalit | | Chandler ED Downtime Tool - GS |
| Report a Breach | Clint Lush at 323-4462 if you have any questions | | Equipment Resources |
| Report an Incident | chine cuan at 323-4402 in you have any questions | | Health Manager |
| Sustainability | 7/13/2017 - 27th Annual Nursing Re | search Papers Day | Kronos Pilot Group Link |
| | | | Nursing Staff |
| OVIHD - Quality | UK HealthCare Nursing Service in collaboration | | Order Sets/Protocols |
| Quality and Patient Safety | Annual Nursing Research Papers Day - "Bringing Nursing Research" | the science to Life: innovations in | PageCenterX |
| Continuous Readiness | | | PatientWorks |
| Workplace Safety | Keynote Speaker: | | SCM Resources |
| | Gail Stern, MSN, PMHCNS-BC | | Staff Manager Info |
| Patient Experience | Administrator, Department of Psychiatry | | Staff Manager Web |
| Infection Prevention | Lehigh Valley Hospital & Health Network | | Login |
| Leadership | Bethlehem, PA | | Transport Tracking XT |
| | Topic: | | Patient Links |
| Physicians | The Evolution of Behavioral Health Integration: N | lew Roles in Nursing | ED Advanced Nursing Protocols |
| Nurses | Date: | | Patient Diet Menus |
| Rehab | Friday, November 10, 2017 | | Patient Education |
| Pharmacy | | | Clinician Links |
| | Location: | | Antibiograms |
| Perioperative Services | Hilton Downtown | | Apheresis Request |
| Respiratory | 369 West Vine Street, Lexington, KY 40507 | | Protocol Behavioral Standards |
| Information Technology | Conference Registration: http://www.ukconce.or | g/default.aspx | Chart Components |
| | 2017 Abstract application: Click here | | Order List |
| PPD | | Read more | Chemo & Hazardous |
| Clinical Engineering | | | Med Database |
| Lab | 7/9/2017 - SCM 16.3 Upgrade: New | Functionality! | Clinical Laboratory Clinical Practice |
| UK HealthCare | The SCM 16.3 Upgrade on July 9th, will bring ne | w functionality including a new Discharge | Guidelines |
| | Tab and Discharge orders that will optimize the | | Clostridium difficile |

| Chandler Emergency Department |
|-------------------------------|
| Chandler Medical Center |
| Good Samaritan |
| Kentucky Children's Hospital |
| Markey Cancer Center |
| CVICU |
| MICU |
| NSICU |
| PICU-NICU |
| SICU |

| | | Cur | | | | | | eptibi | | | | | | |) | | | | | | |
|---|--------------------|------------|----------------------|-----------|-------------|-------------|--------------|--------------|-----------|--------------|-----------|-------------------------|----------|-------------|-------------|-------------|--------------|-------------|-------------------------------|-----------------|------------------------------|
| | | | | | De | velop | ed Da | ate: Fe | ebrua | ry 15, | 2018 | | | - | - | | | | | | |
| | | | | | | Bet | ta-lacta | ms | | | | | Amin | oglyco | sides | FQ | | Other | | Urin | ary |
| Gram-Negative Organism | Number of isolates | Ampicillin | Amipcillin-sulbactam | Aztreonam | Ceftazidime | Ceftriaxone | Cefepime | Cefoxitin | Cefazolin | Ertapenem | Meropenem | Piperacillin-tazobactam | Amikacin | Gentamicin | Tobram ycin | Levofloxadn | Tetracycline | Minocycline | Trimethoprim-sulfamethoxazole | Nitrofurantoin§ | Oral Cephalosporins for UTI§ |
| | _ | | | _ | | | Ente | robact | eriacea | e | | | | | | | | | | | |
| Citrobacter freundii | 54 | R | R | 76 | 75 | 74 | 91 | R | R | 96 | 98 | 87 | 100 | 94 | 91 | 96 | 85 | - | 78 | 100 (21)+ | R |
| Enterobacter (Klebsiella) aerogenes | 68 | R | R | 82 | 81 | 82 | 97 | R | R | 97 | 96 | 79 | 100 | 100 | 100 | 99 | 93 | - | 100 | 9 (23)+ | R |
| Enterobacter cloacae | 199 | R | R | 80 | 79 | 80 | 92 | R | R | 87 | 99 | 83 | 100 | 94 | 93 | 95 | 89 | - | 88 | 32 (41) | R |
| Escherichia coli | 1318 | 42 | 46 | 91 | 94 | 88 | 90 | 92 | 63 | 99 | 100 | 95 | 100 | 89 | 88 | 70 | 72 | - | 68 | 97 (861) | 85 (861 |
| Klebsiella pneumoniae | 403 | R | 81 | 97 | 96 | 94 | 96 | 88 | 84 | 97 | 99 | 93 | 100 | 98 | 97 | 98 | 84 | - | 94 | 38 (174) | 92 (177 |
| Klebsiella oxytoca | 91 | R | 56 | 95 | 98 | 95 | 100 | 98 | 36 | 100 | 100 | 93 | 100 | 97 | 97 | 99 | 97 | 1 | 96 | 90 (31) | 81 (31) |
| Morganella morganii | 51 | R | 14 | 96 | 78 | 80 | 100 | R | R | 98 | 100 | 100 | 100 | 76 | 82 | 75 | R | R | 69 | R | R |
| Proteus mirabilis | 137 | 85 | 91 | 99 | 99 | 96 | 98 | 96 | R | 99 | 100 | 100 | 100 | 85 | 84 | 72 | R | R | 76 | R | R |
| Serratia marcescens | 131 | R | R | 99 | 100 | 93 | 99 | R | R | 98 | 99 | 95 | 100 | 98 | 77 | 99 | 0 | - | 100 | R | R |
| Acinetobacter baumannii+ | 24 | R | 57 | R | 39 | Non 30 | -ferme 43 | nting G R | R | egative R | s 54 | - | 52 | 43 | 52 | 46 | 42 | - | 58 | - | R |
| Acinetobacter Iwoffii | 1 | R | - | R | - | | - | R | R | R | - | | - | | | | (19)+ | | | | R |
| Burkholderia cepacia complex | 9 | R | R | <u> </u> | - | R | - | R | R | R | - | R | R | R | R | - | - | - | - | - | R |
| Pseudomonas aeruginosa | 426 | R | R | 68 | 82 | R | 75 | R | R | R | 77 | 77 | 90 | 87 | 89 | 68 | R | R | R | | R |
| Pseudomonas aeruginosa (Non-CF isolates) | 362 | R | R | 69 | 84 | R | 81 | R | R | R | 81 | 77 | 99 | 88 | 91 | 74 | R | R | R | - | R |
| Pseudomonas aeruginosa (CF isolates) | 64 | R | R | 64 | 71 | R | 44 | R | R | R | 55 | 75 (16)+ | 38 | 67 (15)+ | 83 | 31 | R | R | R | - | R |
| Stenotrophomonas maltophila | 74 | R | R | - | •• | R | - | R | R | R | - | R | R | R | R | 78 | R | 99 | 99 | - | R |
| | | | | | | - | Other | Gram- | negativ | /es | | - | | | | | | | | | |
| Haemophilus influenzae | 131 | 90 (84) | - | - | - | 100 | - | - | - | - | - | - | - | - | - | 100 | 99 | - | 64 | - | - |

Chandler Medical Center (Including Emergency Department)

*The percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient. Organisms with < 15 isolates do not have sensitivities reported due to lack of scientific validity.

+Calculated from fewer than the standard recommendation of 30 isolates; number in parentheses is number of isolates tested

§Data from urinary isolates only

Abbreviations: CF - cystic fibrosis; R - intrinsic resistance; [-] Drug not tested or not indicated

**Selective isolates (ex. multi-drug resistant organisms) were tested but did not achieve threshold for reporting

It's All About Odds – what is the most likely organism? And what is the chance of resistance?

Who is this Greek god? Hint: look at the staff





28yo student w/o PMH, presents with fever, productive cough, and feeling unwell. CXR shows RLL infiltrate. What treatment is most appropriate?

- A. Admit for IV Levofloxacin
- B. Admit for Vancomycin & Pip/tazo
- C. Outpatient Levofloxacin
- D. Outpatient Azithromycin
- E. Admit for IV Ceftriaxone/Azithro

CAP: What Are We Covering?

Most Common Causes of CAP in this previously healthy patient?:


- Typical
 - Strep Pneumoniae
- Atypical
 - Mycoplasma
 - Chlamydophila



To Admit or Not Admit?

• Admit:

- CURB-65 >=2 or CRB-65 >/= 1
- New hypoxia
- Inability to take PO
- Failure of outpatient therapy



CLASSIC REPRINT SERIES

52yo man with DM & COPD, presents with fever, productive cough, and feeling unwell. CXR shows RLL infiltrate. <u>What Treatment is most appropriate?</u>

- A. Admit for IV Levofloxacin
- B. Admit for Vancomycin & Pip/tazo
- C. Outpatient Levofloxacin
- D. Outpatient Azithromycin
- E. Admit for IV Ceftriaxone/Azithro

Pneumonia: What are we covering?

Common Things:


• Strep Pneumo & Atypical

Underlying lung disease – increases risk for Gram (-)'s

- H. Influenzae
- Moraxella
- O Legionella
- Pseudomonas

Diabetes:

O Increases risk for drug resistant strep pneumo





- Healthy patient w/ CAP:
 - Atypical, strep pneumoniae
- Underlying lung disease
 - Gram negatives, legionella
- Comorbid conditions or recent Abx:
 - Drug resistant strep pneumo
- Post-Flu, nursing homes, recent hospitalization, cavitary PNA:
 - MRSA

Table 8. Epidemiologic conditions and/or risk factors related to specific pathogens in community-acquired pneumonia.

| Condition | Commonly encountered pathogen(s) |
|--|--|
| Alcoholism | Streptococcus pneumoniae, oral anaerobes, Klebsiella pneumoniae, Acinetobacter species, Mycobacterium tuberculosis |
| COPD and/or smoking | Haemophilus influenzae, Pseudomonas aeruginosa, Legionella species, S. pneumoniae, Moraxella carar- rhalis, Chlamydophila pneumoniae |
| Aspiration | Gram-negative enteric pathogens, oral anaerobes |
| Lung abscess | CA-MRSA, oral anaerobes, endemic fungal pneumonia, M. tuberculosis, atypical mycobacteria |
| Exposure to bat or bird droppings | Histoplasma capsulatum |
| Exposure to birds | Chlamydophila psittaci (if poultry: avian influenza) |
| Exposure to rabbits | Francisella tularensis |
| Exposure to farm animals or parturient cats | Coxiella burnetti (Q fever) |
| HIV infection (early) | S. pneumoniae, H. influenzae, M. tuberculosis |
| HIV infection (late) | The pathogens listed for early infection plus Pneumocys- tis jirovecii, Cryptococcus, Histoplasma, Aspergillus, atypical mycobacteria (especially Mycobacterium kansasii), P. aeruginosa, H. influenzae |
| Hotel or cruise ship stay in previous 2 weeks | Legionella species |
| Travel to or residence in southwestern United States | Coccidioides species, Hantavirus |
| Travel to or residence in Southeast and East Asia | Burkholderia pseudomallei, avian influenza, SARS |
| Influenza active in community | Influenza, S. pneumoniae, Staphylococcus aureus, H. influenzae |
| Cough >2 weeks with whoop or posttussive vomiting | Bordetella pertussis |
| Structural lung disease (e.g., bronchiectasis) | Pseudomonas aeruginosa, Burkholderia cepacia, S. aureu |
| Injection drug use | S. aureus, anaerobes, M. tuberculosis, S. pneumoniae |
| Endobronchial obstruction | Anaerobes, S. pneumoniae, H. influenzae, S. aureus |
| In context of bioterrorism | Bacillus anthracis (anthrax), Yersinia pestis (plague), Francisella tularensis (tularemia) |

22yo student, presents with fever, headache, nausea, neck stiffness.

What are your antibiotics of choice?

- A. IV Ceftriaxone
- B. IV Vancomycin
- C. IV Vanc + Ceftriaxone
- D. IV Vanc + Ceftriaxone + Ampicillin


Bacterial Meningitis: What are we Covering?

Community Acquired Meningitis:

- N. Meningitis
- Strep Pneumo
- Together account for > 80%

But why vancomycin?

• Drug resistant strep pneumo



55yo lady, presents with fever, headache, nausea, neck stiffness.

What are your antibiotics of choice?

- A. IV Ceftriaxone
- B. IV Vancomycin
- C. IV Vanc + Ceftriaxone
- D. IV Vanc + Ceftriaxone + Ampicillin

Bacterial Meningitis: What are we covering?

Common:

- O Strep. Pneumo
- 0 N. meningitides

Why ampicillin?

- O Listeria
- Who?
 - > 50

• Altered cell mediated immunity: HIV, immunosuppressants

Bacterial Meningitis: Special Considerations

Hospital Acquired or Neurosurgical Procedures:

- o MRSA
- Pseudomonas
- Gram negatives

Regimen:

- MRSA: vancomycin
- Gram (-)/Pseudomonas: cefepime/ceftazidime or meropenem

Table 4. Recommendations for empirical antimicrobial therapy for purulent meningitis based on patient age and specific predisposing condition (A-III).

| Predisposing factor | Common bacterial pathogens | Antimicrobial therapy | | | | | | |
|------------------------|---|---|--|--|--|--|--|--|
| lge | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| 2–50 years | N . meningitidis, S. pneumoniae | Vancomycin plus a third-generation cephalosporin ^{a,b} | | | | | | |
| >50 years | S. pneumoniae, N. meningitidis, L. monocytogenes, aerobic gram-negative bacilli | Vancomycin plus ampicillin plus a third-generation cephalosporin ^{a,b} | | | | | | |
| lead trauma | | | | | | | | |
| Basilar skull fracture | S. pneumoniae, H. influenzae, group A β-hemolytic streptococci | Vancomycin plus a third-generation cephalosporin ^a | | | | | | |
| Penetrating trauma | Staphylococcus aureus, coagulase-negative staphylo- cocci (especially Staphylococcus epidermidis), aer- obic gram-negative bacilli (including Pseudomonas aeruginosa) | Vancomycin plus cefepime, vancomycin plus ceftazi- dime, or vancomycin plus meropenem | | | | | | |
| Postneurosurgery | Aerobic gram-negative bacilli (including <i>P. aeruginosa</i>), <i>S</i> . aureus, coagulase-negative staphylococci (es- pecially <i>S. epidermidis</i>) | Vancomycin plus cefepime, vancomycin plus ceftazi- dime, or vancomycin plus meropenem | | | | | | |
| CSF shunt | Coagulase-negative staphylococci (especially <i>S. epi- dermidis</i>), <i>S. aureus</i> , aerobic gram-negative bacilli (including <i>P. aeruginosa</i>), <i>Propionibacterium acnes</i> | Vancomycin plus cefepime, ^e vancomycin plus ceftaz dime, ^e or vancomycin plus meropenem ^e | | | | | | |

Suspicion for bacterial meningitis

Yes

Immunocompromise, history of CNS disease, new onset seizure, papilledema, altered consciousness, or focal neurologic deficit;^a or delay in performance of diagnostic lumbar puncture

No Blood cultures and lumbar puncture STAT ↓ Dexamethasone^b + empirical antimicrobial therapy^{c,e} Yes

Perform lumbar puncture

ImbarBlood cultures STATImpiricalImpirical $py^{c,e}$ Dexamethasone^b + empirical
antimicrobial therapy^cImpiricalImpirical
Antimicrobial therapy^c</

CSF findings c/w bacterial meningitis

Yes

No

Yes


Dexamethasone^b + empirical antimicrobial therapy^c Dexamethasone^b + targeted antimicrobial therapy^d A 34 y/O M presents with pain, swelling and erythema over his left thigh. On exam there is a 3cm area of fluctuance with 6cm or overlying erythema.

In addition to I&D, which is the most treatment?

A.Cephalexin B.Bactrim

C.Levaquin

D.Dicloxacillin



Cellulitis: What are we Covering?

- Most Common Pathogens?
 - O Staph
 - O Strep
- Purulent:
 - O MSSA/MRSA

Special MRSA considerations for non-purulent infections:

• Penetrating trauma, IVDU, h/o or current MRSA infection, sepsis



Cellulitis Therapies: (2014 IDSA SSTI Guidelines)

Strep/MSSA – First Line:

O PO ?: dicloxacillin, cephalexin, amoxicillin-clavulanate, macrolide
O IV ?: penicillin, cefazolin, ceftriaxone

MRSA Coverage – Consider if purulence/abscess or risk factors:
 PO?: doxycycline, Bactrim, clindamycin, linezolid
 IV?: daptomycin, vancomycin, ceftaroline

Skin & Soft Tissue Special Circumstances:

Bite wound:

• Think Anaerobes: Tx with augmentin or clindamycin

Diabetic Foot Infection:

Often polymicrobial including gram negatives (incl pseudomonas) and anaerobes
 Tx: augmentin, Levaquin, clindamycin, doxycycline, zosyn, vancomycin, linezolid
 Oconsider adding MRSA coverage for purulence/risk factors

27 YO WOMAN WITH DYSURIA, HEMATURIA, AND INCREASED URINARY FREQUENCY PRESENTS TO CLINIC. SHE IS HEMODYNAMICALLY STABLE AND TOLERATING PO.

WHAT ANTIBIOTIC IS MOST APPROPRIATE?

- A. Nitrofurantion
- B. Ciprofloxacin
- C. Ceftriaxone
- D. Zosyn

Urinary Tract Infections:

What are we covering?

- Most common
 - E. Coli
 - Klebsiella

O Other: Enterococcus; Proteus, Pseudomonas, staph saprophyticus

UTI's Treatment (IDSA)

Uncomplicated Cystitis:

O PO: Bactrim, Nitrofurantoin (fosfomycin, beta lactams)O IV: Rocephin, unasyn

Pyelonephritis:

• PO: Levaquin, Bactrim if susceptible

○ IV: Rocephin

UTI: special points

Enterococcal UTI:

• No cephalosporins

O Ampicillin, Fosfomycin, Vanc or Dapto

Chandler E. Coli Strains have high fluoroquinolone resistance

Cannot use nitrofurantoin for pyelonephritis

Only Tx asymptomatic bacteriuria in:

• Pregnancy & Upcoming GU surgery

